Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Jim Cramer once confidently backed Pfizer, praising its pipeline and high dividend, forecasting a big post-COVID comeback. “I ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Real-time index price for TSX Composite Dividend Index (TXDC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

In light of this, income investors may be better off looking at ASX dividend shares instead of term deposits. The first ASX dividend share that could be a buy according to analysts is global ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.